Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy
Christian R. Kahlert, Andrea Bregenzer, Christine Gutmann, Synove Otterbech, Matthias Hoffmann, Patrick Schmid & Pietro Vernazza
For selected patients, rb-PMT might be a valid long-term treatment strategy. Nevertheless, even after 12 months of full HIV-RNA suppression, more than 1/3 of patients may still develop failure in either plasma or CSF. Given the observation of isolated CSF failure, treatment monitoring with regular lumbar puncture should be recommended in rb-PMT. Only monotherapy with atazanavir/r was successful beyond 39 months. Monotherapy failure was significantly associated with a shorter duration of complete HIV-RNA suppression in plasma prior to rb-PMT start. Further investigation is needed to better identify predictors for patients that will qualify for successful long-term rb-PMT.
|citation||Kahlert C R, Bregenzer A, gutmann c, Otterbech S, Hoffmann M, Schmid P, Vernazza P. Late treatment failures in cerebrospinal fluid in patients on long-term maintenance ART with ritonavir-boosted protease PI monotherapy. Infection 2015;.|
|type||journal paper/review (English)|
|date of publishing||11-12-2015|